CanSino Biologics Inc Cash Flow-to-Debt Ratio
CanSino Biologics Inc cash flow-to-debt ratio. CanSino Biologics Inc (CJH) has a Cash Flow-to-Debt Ratio of -0.10x as of June 2023, meaning its operating cash flow of €-392.00 Million could theoretically repay 0% of its total liabilities (€3.93 Billion) in one year. Check CanSino Biologics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of CanSino Biologics Inc (2016–2025)
Cash flow-to-debt ratio of CanSino Biologics Inc from 2016 to 2025. Historical debt coverage capacity for CanSino Biologics Inc across 10 annual periods. Check how aggressively does CanSino Biologics Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
CanSino Biologics Inc Cash Flow-to-Debt Ratio by Year (2016–2025)
CanSino Biologics Inc cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for CanSino Biologics Inc. For the full cash flow conversion analysis, see CanSino Biologics Inc (CJH) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.04x | €77.86 Million | €2.22 Billion | ▲ +163.2% |
| 2024 | -0.06x | €-168.79 Million | €3.05 Billion | ▲ +75.6% |
| 2023 | -0.23x | €-916.25 Million | €4.03 Billion | ▲ +48.2% |
| 2022 | -0.44x | €-1.85 Billion | €4.22 Billion | ▼ -171.1% |
| 2021 | 0.62x | €2.05 Billion | €3.33 Billion | ▲ +219.3% |
| 2020 | -0.52x | €-349.93 Million | €677.22 Million | ▼ -5.2% |
| 2019 | -0.49x | €-154.25 Million | €313.98 Million | ▼ -16.6% |
| 2018 | -0.42x | €-123.64 Million | €293.56 Million | ▼ -93.8% |
| 2017 | -0.22x | €-56.30 Million | €259.03 Million | ▲ +29.4% |
| 2016 | -0.31x | €-34.38 Million | €111.70 Million | — |